BACKGROUND: Although the cellular and molecular biological effects of interferon (IFN)-alpha have been well-investigated, the effects of IFN-gamma are less understood. MATERIALS AND METHODS: Eleven human myeloma cell lines with various myeloma-specific chromosomal translocations and overexpression of oncogenes were cultured with 1000 U/ml of IFN-gamma. In the KMS-20 cells, which showed growth inhibition due to IFN-gamma, trail expression, status of the Janus kinase (JAK)/STAT pathway were analyzed. RESULTS: KMS-20 cells showed marked up-regulation of trail, activation of STAT1 and TRAIL hyperproduction induced by IFN-gamma. CONCLUSION: The effects of IFN-gamma on growth inhibition of KMS-20 cells were characterized by activation of the JAK/STAT signalling pathway, particularly STAT1 phosphorylation, enhanced secretion of TRAIL, and auto/paracrine usage of secreted TRAIL to induce apoptotic cell death. From these results, IFN-gamma may be considered one of the drugs to be used in future multidrug chemotherapeutic regimens for myeloma patients.
BACKGROUND: Although the cellular and molecular biological effects of interferon (IFN)-alpha have been well-investigated, the effects of IFN-gamma are less understood. MATERIALS AND METHODS: Eleven humanmyeloma cell lines with various myeloma-specific chromosomal translocations and overexpression of oncogenes were cultured with 1000 U/ml of IFN-gamma. In the KMS-20 cells, which showed growth inhibition due to IFN-gamma, trail expression, status of the Janus kinase (JAK)/STAT pathway were analyzed. RESULTS: KMS-20 cells showed marked up-regulation of trail, activation of STAT1 and TRAIL hyperproduction induced by IFN-gamma. CONCLUSION: The effects of IFN-gamma on growth inhibition of KMS-20 cells were characterized by activation of the JAK/STAT signalling pathway, particularly STAT1 phosphorylation, enhanced secretion of TRAIL, and auto/paracrine usage of secreted TRAIL to induce apoptotic cell death. From these results, IFN-gamma may be considered one of the drugs to be used in future multidrug chemotherapeutic regimens for myelomapatients.
Authors: Amriti R Lulla; Yan Zhou; Marie D Ralff; Avital Lev; David T Dicker; Wafik S El-Deiry Journal: Am J Cancer Res Date: 2022-01-15 Impact factor: 6.166
Authors: Martin Hasselblatt; Jasmin Bartl; Marc Remke; Lena Blümel; Nan Qin; Johannes Berlandi; Eunice Paisana; Rita Cascão; Carlos Custódia; David Pauck; Daniel Picard; Maike Langini; Kai Stühler; Frauke-Dorothee Meyer; Sarah Göbbels; Bastian Malzkorn; Max C Liebau; João T Barata; Astrid Jeibmann; Kornelius Kerl; Serap Erkek; Marcel Kool; Stefan M Pfister; Pascal D Johann; Michael C Frühwald; Arndt Borkhardt; Guido Reifenberger; Claudia C Faria; Ute Fischer Journal: Cell Death Dis Date: 2022-09-20 Impact factor: 9.685
Authors: Sanjay Varikuti; Steve Oghumu; Mohamad Elbaz; Greta Volpedo; Dinesh K Ahirwar; Pablo C Alarcon; Rachel H Sperling; Ellen Moretti; Marissa S Pioso; Jennifer Kimble; Mohd W Nasser; Ramesh K Ganju; Cesar Terrazas; Abhay R Satoskar Journal: Oncoimmunology Date: 2017-08-14 Impact factor: 8.110